Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals to Present at the Virtual Investor KOL Roundtable


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time: https://mms.businesswire.com/media/20191121005600/en/479704/5/Lantheus%C2%AE_Holdings_RGB.jpg
Lantheus Holdings to Host Third Quarter 2020 Earnings Conference Call and Webcast on November 5, 2020 at 8:00 a.m. Eastern Time


Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 5, 2020, to discuss its financial and

Therma Bright and Orpheus Medica Advance CoviSafe™ Rapid Saliva Test to Formal Product Developmental Phase

 

-          Successful Completion of the feasibility Studies followed by engagement of nanoComposix to accelerate the development of CoviSafe™

 

Toronto, Ontario--(October 21, 2020) –

ICON Reports Third Quarter 2020 Results : https://mms.businesswire.com/media/20191114005374/en/602293/5/ICON_Positive_logo_PNG_%28nostrap%29.jpg
ICON Reports Third Quarter 2020 Results


ICON plc (NASDAQ: ICLR), a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health

University Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in New Orleans : http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
University Medical Center and Humana Sign Agreement, Expanding Humana’s Medicare Advantage Provider Network in New Orleans


University Medical Center New Orleans, a part of LCMC Health, and Humana Inc. (NYSE: HUM), a leading health and well-being company, have signed an in-network agreement, expanding access to care for

Humana Joins Forces with DAV (Disabled American Veterans): http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana Joins Forces with DAV (Disabled American Veterans)


Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has entered into an agreement with DAV (Disabled American Veterans), an organization whose mission is

Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020http://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Data From Pfizer’s Adult and Pediatric Clinical Trial Programs for 20-Valent Pneumococcal Conjugate Vaccine Presented at IDWeek 2020


Pfizer Inc. (NYSE:PFE) today announced the full analysis from one of its Phase 3 studies (NCT03760146), which evaluated the safety and immunogenicity of its 20-valent pneumococcal conjugate vaccine

STAAR Surgical to Report Third Quarter Results on November 4, 2020: https://mms.businesswire.com/media/20200413005098/en/683092/5/STAAR_Surgical_Logo_Primary_Lockup_%28Sunise_Teal%29.jpg
STAAR Surgical to Report Third Quarter Results on November 4, 2020


STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release

Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5: https://mms.businesswire.com/media/20191107005162/en/305545/5/Clovis_Logo_Process_Color.jpg
Clovis Oncology to Announce Third Quarter 2020 Financial Results and Host Webcast Conference Call on November 5


Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its third quarter 2020 financial results on Thursday, November 5, 2020, before the open of the U.S. financial markets. Clovis’ senior management

Simulations Plus Releases GastroPlus® Version 9.8: https://mms.businesswire.com/media/20200318005128/en/780378/5/BusinessWireLogo.jpg
Simulations Plus Releases GastroPlus® Version 9.8


Simulations Plus, Inc. (Nasdaq: SLP), the leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that

Chief Medical Officers from Boston Scientific, Illumina, Johnson & Johnson, and QIAGEN to Keynote Veeva MedTech Summit Online: https://mms.businesswire.com/media/20191104005259/en/747666/5/Veeva_Logo.jpg
Chief Medical Officers from Boston Scientific, Illumina, Johnson & Johnson, and QIAGEN to Keynote Veeva MedTech Summit Online


Veeva Systems (NYSE: VEEV) today announced the featured keynote speakers at 2020 Veeva Medical Device & Diagnostics Summit Online. Chief medical officers from Boston Scientific, Illumina, Johnson &amp

NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting: https://mms.businesswire.com/media/20191111005579/en/744572/5/LOGO_NANO_EXPANDING_LIFE.jpg
NANOBIOTIX Announces Four Presentations at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting


Regulatory News:



NANOBIOTIX (Paris:NANO) (Euronext: NANO - ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today

Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus : https://mms.businesswire.com/media/20191103005014/en/691947/5/VP_logo_rgb.jpg
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with pruritus


Regulatory News:


This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/



Vifor Pharma and Cara Therapeutics, Inc

Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020: https://mms.businesswire.com/media/20191114005606/en/588971/5/Quidel_Horiz_Sml_Vector_CMYK.jpg
Quidel to Hold Third Fiscal Quarter 2020 Financial Results Conference Call on October 29th, 2020


Quidel Corporation (NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, will report third fiscal quarter 2020 financial

Medigene AG: Medigene and Cytovant enter into service agreement for DC vaccine manufacturing process development

 

Planegg/Martinsried (19.10.2020) - Medigene AG (MDG1, Frankfurt, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell immunotherapies for the

EnWave Announces Normal Course Issuer Bid

Vancouver, B.C., October 19, 2020

 

EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave,” or the "Company - https://www.commodity-tv.com/play/enwave-update-on-covid-19-impact-rev-machine-sales

Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24221/330px-Agilent.svg.png
Agilent to Showcase Their Commitment to Sustainability at analytica virtual 2020


Agilent Technologies Inc. (NYSE: A) today announced that their 1220, 1260, and 1290 Infinity II LC product families have received the My Green Lab accountability, consistency, and transparency

Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers: https://mms.businesswire.com/media/20191209005543/en/255636/5/logo_TRANSGENE.jpg
Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab in Advanced HPV-positive Cancers


Regulatory News:



Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of the

Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical

Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales

Qilu Pharmaceutical to receive an exclusive license to develop and commercialize

IMV Inc. Re-establishes At-the-Market Facility: https://mms.businesswire.com/media/20200225005324/en/775456/5/IMV_Logos_IMV-Logo_BrandStatement.jpg
IMV Inc. Re-establishes At-the-Market Facility


IMV Inc. (TSX: IMV; NASDAQ: IMV) (the "Company" or “IMV”), a clinical-stage biopharmaceutical company, today announced that it has entered into an equity distribution agreement, dated October 16

Charles River Laboratories Adds George Llado to Board of Directors: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Adds George Llado to Board of Directors


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the appointment of George Llado, Senior Vice President and Chief Information Officer of Alexion Pharmaceuticals, Inc., to

Medigene AG: Three Medigene poster presentations at SITC Annual Meeting

 

Planegg/Martinsried (15.10.2020) - Scientists of Medigene AG (Medigene, FSE: MDG1, Prime Standard), a clinical stage immuno-oncology company focusing on the development of T cell

Premier Inc. Contracts with HHS on Data-Driven Initiative to Improve U.S. Maternal Health : https://mms.businesswire.com/media/20191105005372/en/754182/5/PR_LogoSpec_%282%29.jpg
Premier Inc. Contracts with HHS on Data-Driven Initiative to Improve U.S. Maternal Health


Premier Inc. (NASDAQ: PINC) today announced a new, two-year, $8 million national partnership with the U.S. Department of Health and Human Services (HHS) Office of Women’s Health to leverage

Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24221/330px-Agilent.svg.png
Agilent Vaya Raman Raw Material ID Verification System Receives 2020 R&D 100 Award


Agilent Technologies Inc. (NYSE: A) today announced that the Agilent Vaya Raman raw material identity verification system has received a 2020 R&D 100 Award in the Analytical/Test category. The

NeutriSci Enters the Second Highest Grossing Market with New Distribution in the State of Washington

Vancouver, British Columbia October 15, 2020 – NeutriSci International Inc. (“NeutriSci” or the “Company”) (TSX-V: NU, OTCQB: NRXCF, FRANKFURT: 1N9), an innovative technology company